Maze Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Maze Therapeutics

11/08/2026 21:16

Maze Therapeutics, Inc. MAZE.OQ reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -77 cents.  The mean expectation of eleven analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -85 cents to -44 cents per share.
Reported revenue was zero​; analysts expected $2.00 million. 
Maze Therapeutics, Inc.'s reported EPS for the quarter was a loss of 76 cents​.
The company reported a quarterly loss of $44.73 million.
Maze Therapeutics, Inc. shares had fallen by 8.6% this quarter and lost 34.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Maze Therapeutics, Inc. is $55.50, about 50.8% above its last closing price of $27.28
This summary was machine generated from LSEG data August 11 at 08:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.73
-0.76
Missed
Mar. 31 2026 
-0.55
-0.45
Beat
Dec. 31 2025 
-0.71
-0.65
Beat
Sep. 30 2025 
-0.71
-0.66
Beat